- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01290289
Analgesia in Labor, a Prospective Parallel Study to Compare Regional Analgesia and Intravenous (IV) Pethidine Analgesia
Analgesia in Labor, a Prospective Parallel Single Blind Study to Compare Regional Analgesia (Combined Spinal Epidural Analgesia (CSE), Epidural Analgesia (E)) and Intravenous (IV) Pethidine Analgesia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective parallel single blind study, which was approved by the institutional review board of El-Galaa Teaching Hospital, and the research and ethics committee of Faculty of Pharmacy, Cairo University.
This hospital per si was selected for the study because it is large hospital that could provide the study with a diverse population. It has a population of various socio-economic statuses. This would provide the study with a sample of patients with a wide range of characteristics.
Sixty full-term, ASA physical status I or II nulliparous women in active labor with cervical dilatation of 5 cm and cephalic presenting fetus were randomly assigned to one of five groups after providing informed consent.
- Group 1: received CSE analgesia, where 25 µg of fentanyl was injected intrathecally and a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected upon request.
- Group 2: received CSE analgesia, where 25 µg of fentanyl was injected intrathecally and a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected upon request.
- Group 3: received 50µg of E fentanyl analgesia which was injected intrathecally and a bolus of 10 ml of 0.5% lidocaine was administered through the catheter, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8% upon request.
- Group 4: received analgesia, where 50 µg of E fentanyl were injected intrathecally and a bolus dose of 10 ml of 0.125% bupivacaine was administered through the catheter, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25% upon request.
- Group 5: 50 mg of IV pethidine was administered as a loading dose, followed by 0.5 mg/kg, with a total maximum limit of 130 mg.
Study Subjects Excluding Criteria Patients who had diabetes mellitus, neurological disease, pre-eclampsia, or patients who had received parenteral analgesics or patients with contraindication to E or spinal analgesia, or patients with sensitivity to local anesthetics or opioids were excluded from the study.
Study Method All the recruited subjects were screened before the administration of any analgesia. Systolic and diastolic pressures, heart rate and peripheral oxygen saturation (SpO2) were monitored. Fetal heart rate (FHR) was monitored using an external cardiotocograph monitor (Partoconter NST Nihon Kohden).
For the E groups, the degree of motor block was assessed according to a modified Bromage scale (Grade I: free movement of legs and feet; Grade II: just able to flex knees with free movement of feet; Grade III: unable to flex knees, but with free movements of feet; Grade IV: unable to move legs or feet) before administration of E analgesia, 10 and 30 minutes after the first dose. The start of the analgesia was regarded as time 0. The duration of analgesia was taken as the time from the beginning of analgesic injection (time 0) to the time of request for additional analgesia.
The number of analgesic top-ups was recorded and the intervals between each top-up, in addition to the volume and concentration of the drug injected.
The Visual Analogue Pain Scale (VAS) (0 mm = no pain, 100 mm = worst pain imaginable) was measured before administration of analgesia, 10 and 30 minutes after administration of each analgesic dose until the delivery of the baby.
Maternal arterial pressures, heart rate, SpO2, and FHR were noted before the analgesia was given, and afterwards every 30 minutes until delivery.
Maternal temperature was recorded before starting the analgesic regimen and thereafter every hour till the end of labor. Fever was defined as temperature of ≥ 38˚C.
The duration of each stage of labor together with the mode of delivery were recorded.
The total volume of drug injected, total concentration of drug injected, 1-min and 5-min APGAR scores, weight of the neonate were recorded.
Any experienced drug related problem by any of the recruited subjects were recorded.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- El-Galaa Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
full-term, ASA physical status I or II nulliparous women in active labor with cervical dilatation of 5 cm and cephalic presenting fetus
Exclusion Criteria:
Patients who had diabetes mellitus, neurological disease, pre-eclampsia, or patients who had received parenteral analgesics or patients with contraindication to E or spinal analgesia, or patients with sensitivity to local anesthetics or opioids were excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Epidura, combined spinal epidura & IV
Gp 1: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.5% lidocaine injected epidurally. Gp 2: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.0625% bupivacaine injected epidurally. Gp 3: received 50µg of E fentanyl analgesia, injected intrathecally & a bolus of 10 ml of 0.5% lidocaine, followed by lidocaine E top-ups. Gp 4: received 50µg of E fentanyl injected intrathecally and a bolus dose of 10 ml of 0.125% bupivacaine, followed by E bupivacaine top-ups. Gp 5: 50mg of IV pethidine was administered as a loading dose, followed by 0.5 mg/kg. |
Gp 1: received CSE analgesia: 25µg of fentanyl & a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected. Gp 2: received CSE analgesia: 25µg of fentanyl & a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected. Gp 3: received 50µg of E fentanyl analgesia & a bolus of 10 ml of 0.5% lidocaine was administered, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8%. Gp 4: received analgesia: 50µg of E fentanyl & a bolus dose of 10 ml of 0.125% bupivacaine was administered, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25%. Gp 5: 50mg of IV pethidine was administered as loading dose, followed by 0.5 mg/kg. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Analogue Scale to assess pain control
Time Frame: 24 hours
|
The Visual Analogue Pain Scale (VAS) (0 mm = no pain, 100 mm = worst pain imaginable) was measured before administration of analgesia, 10 and 30 minutes after administration of each analgesic dose until the delivery of the baby.
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The degree of motor block
Time Frame: 24 hours
|
The degree of motor block was assessed according to a modified Bromage scale (Grade I: free movement of legs and feet; Grade II: just able to flex knees with free movement of feet; Grade III: unable to flex knees, but with free movements of feet; Grade IV: unable to move legs or feet) before administration of E analgesia, 10 and 30 minutes after the first dose.
The start of the analgesia was regarded as time 0. The duration of analgesia was taken as the time from the beginning of analgesic injection (time 0) to the time of request for additional analgesia.
|
24 hours
|
|
Number of top-ups
Time Frame: 24 hours
|
The number of analgesic top-ups was recorded and the intervals between each top-up, in addition to the volume and concentration of the drug injected.
|
24 hours
|
|
Adverse effects
Time Frame: 24 hours
|
Any experienced drug related problem by any of the recruited subjects were recorded.
|
24 hours
|
|
Labour Duration
Time Frame: 24 hours
|
The duration of each stage of labor together with the mode of delivery were recorded.
|
24 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Nirmeen Sabry, Ph.D, Cairo University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 6111972
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Labor Active Dilated Cm
-
Hospital Universitario La PazRecruitingLabor Active Dilated CmSpain
-
Assiut UniversityNot yet recruitingNormal Pregnancy | Labor Active Dilated Cm
-
Arrowhead Regional Medical CenterCompletedLabor | Labor Complication | Labor Delivery | Labor Dystocia | Uterine Contraction | Labor Active Dilated Cm | Labor DurationUnited States
-
Ataturk UniversityCompletedPregnancy | No Pregnancy Complications | Cervical Dilatation of 4-6 cm (Early Active Phase) | MuslimTurkey (Türkiye)
-
University Hospitals Cleveland Medical CenterMelissa March; Alison Bauer; Gaetan Pettigrew; Daisy Hassani; Celina CunananWithdrawnEffect of Carbohydrate Ingestion During Active Labor
-
Sheba Medical CenterTel Aviv UniversityUnknownHealth Preterm Infants With no Active Disease | Human Milk Nutrition | Incubator StayIsrael
-
Linkoeping UniversityCompletedMaternal Obesity During Childbirth | Labor; Arrested Active PhaseSweden
Clinical Trials on Epidura, CSE & IV
-
IWK Health CentreCompletedPregnancy | Labor PainCanada
-
Arga Medtech SAActive, not recruitingAtrial FibrillationCroatia, Georgia
-
Arga Medtech SARecruitingAtrial Fibrillation (AF) | Paroxysmal AF | Persistant Atrial FibrillationUnited States, Netherlands, Croatia, Belgium, Lithuania, Czechia
-
Mayo ClinicUniversity of British ColumbiaEnrolling by invitationAnalgesia | AnesthesiaUnited States, Canada
-
Charite University, Berlin, GermanyUnknownElective Cesarean SectionGermany
-
Western University, CanadaUnknownTo Determine the Onset of Analgesia (Numerical Rating Scale for Pain = 1) in Minutes
-
Istanbul University - CerrahpasaActive, not recruitingNeuromuscular Inhibition vs Muscle Energy Techniques With Core Exercises in Mechanical Low Back PainChronic Mechanical Low Back PainTurkey (Türkiye)
-
Northwestern UniversityTerminatedPregnancy | Prolonged First Stage of Labor | Effects of; Anesthesia, in Labor and DeliveryUnited States
-
Northwestern UniversityTerminatedPregnancy | Prolonged First Stage of Labor | Effects of; Anesthesia, in Labor and DeliveryUnited States
-
University of Wisconsin, MadisonGE HealthcareNot yet recruitingMetastatic Castration-resistant Prostate CancerUnited States